ropinirole has been researched along with Abnormal Movements in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead." | 4.81 | Two advances in the management of Parkinson disease. ( Montgomery, EB, 2002) |
| "Long-term levodopa therapy for Parkinson's disease is complicated by the development of motor fluctuations and abnormal involuntary movements." | 2.41 | Ropinirole for levodopa-induced complications in Parkinson's disease. ( Clarke, CE; Deane, KH, 2000) |
| "Long-term levodopa therapy for Parkinson's disease is complicated by the development of motor fluctuations and abnormal involuntary movements." | 2.41 | Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. ( Clarke, CE; Deane, KH, 2000) |
| "Ropinirole was weakly neuroprotective in this model." | 1.32 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. ( Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gungabissoon, U | 1 |
| Kirichek, O | 1 |
| El Baou, C | 1 |
| Galwey, N | 1 |
| Montgomery, EB | 1 |
| Millan, MJ | 1 |
| Di Cara, B | 1 |
| Hill, M | 1 |
| Jackson, M | 1 |
| Joyce, JN | 1 |
| Brotchie, J | 1 |
| McGuire, S | 1 |
| Crossman, A | 1 |
| Smith, L | 1 |
| Jenner, P | 1 |
| Gobert, A | 1 |
| Peglion, JL | 1 |
| Brocco, M | 1 |
| Clarke, CE | 2 |
| Deane, KH | 2 |
| Müngersdorf, M | 1 |
| Sommer, U | 1 |
| Sommer, M | 1 |
| Reichmann, H | 1 |
3 reviews available for ropinirole and Abnormal Movements
| Article | Year |
|---|---|
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Ther | 2002 |
Ropinirole for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopam | 2000 |
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Park | 2000 |
1 trial available for ropinirole and Abnormal Movements
| Article | Year |
|---|---|
High-dose therapy with ropinirole in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias | 2001 |
2 other studies available for ropinirole and Abnormal Movements
| Article | Year |
|---|---|
Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Dopamine Agonists; Dosa | 2020 |
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopa | 2004 |